Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics is a clinical-stage oncology company developing small-molecule therapies for patients with genetically defined cancers. Its MasterKey therapies are designed to target families of cancer-driving mutations. The lead product candidate, silevertinib, is an oral, brain-penetrant EGFR inhibitor being studied in Phase 2 trials for EGFR-mutant non-small cell lung cancer; the company is preparing a Phase 2 trial in newly diagnosed EGFR-altered glioblastoma. Its pipeline also includes BDTX-4876, a development-stage FGFR2/3 inhibitor, and BDTX-4933, a clinical-stage RAF inhibitor licensed globally to Servier, which leads its development and commercialization. Black Diamond Therapeutics earns licensing income and is eligible for development and commercial sales milestone payments and tiered royalties from Servier for BDTX-4933. The company is based in Cambridge, Massachusetts.
No SEC Form 4 filings for $BDTX in the last 30 days.
See all $BDTX insider activity →Stifel raised its price target for Black Diamond Therapeutics (BDTX) to $14.00 from $8.00, citing encouraging Phase 2 trial data and FDA alignment on a Phase 3 trial. The stock trades at $1.86, with analyst targets ranging from $8 to $14. The company reported Q3 2026 results and has a cash runway into 2028.
Black Diamond Therapeutics (BDTX) reported a Q3 loss of $10 million, or 17 cents per share, missing analyst expectations of a 3-cent loss per share. Shares closed at $1.86, down from $3.89 a year ago.
Black Diamond Therapeutics reported a Q3 2026 net loss of $10.0M and $102.0M in cash. Phase 2 results for silevertinib in NSCLC showed a 60% response rate and 15.0 months of progression-free survival. The company plans a Phase 3 trial, pending FDA feedback.
Over the past 7 days, AlphAI's AI scored 8 news stories mentioning BDTX (Black Diamond Therapeutics, Inc.). Coverage has skewed bullish: 5 bullish, 0 neutral, and 3 bearish.
Recent BDTX coverage spans technology, earnings and financial news.
Analyst upgrade based on positive trial data and regulatory progress.
Earnings miss likely triggers sell pressure.
Strong Phase 2 results and FDA encouragement could lift the stock.
Positive Phase 2 data and FDA encouragement could lift the stock as investors price in a higher probability of approval.
Strong trial results and favorable FDA feedback likely drive upside pressure on BDTX.
AlphAI scores every news story that mentions BDTX with an AI model for sentiment and relevance, and aggregates insider trades from Black Diamond Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Stifel raised its price target for Black Diamond Therapeutics (BDTX) to $14.00 from $8.00, citing encouraging Phase 2 trial data and FDA alignment on a Phase 3 trial. The stock trades at $1.86, with analyst targets ranging from $8 to $14. The company reported Q3 2026 results and has a cash runway into 2028.
Black Diamond Therapeutics (BDTX) reported a Q3 loss of $10 million, or 17 cents per share, missing analyst expectations of a 3-cent loss per share. Shares closed at $1.86, down from $3.89 a year ago.
Black Diamond Therapeutics reported a Q3 2026 net loss of $10.0M and $102.0M in cash. Phase 2 results for silevertinib in NSCLC showed a 60% response rate and 15.0 months of progression-free survival. The company plans a Phase 3 trial, pending FDA feedback.
Black Diamond Therapeutics (BDTX) reported updated Phase 2 results for silevertinib, showing strong CNS activity and longer progression-free survival than current treatments. The FDA supports a potential registration path for all first-line EGFR-NCM NSCLC patients. The company has $102.0 million in cash to fund operations into 2028. BDTX will host an investor call and participate in a conference.
Black Diamond Therapeutics, Inc. (BDTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update • Updated Phase 2 results demonstrate robust CNS activity, including 86% CNS-ORR
Black Diamond Therapeutics, Inc. (BDTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update • Presented positive Phase 2 results for silevertinib in frontline patients with non-classical EGFRm NSCLC at the 2026 ASCO Annual Meeting, including that no patients developed
Black Diamond Therapeutics (Nasdaq: BDTX) reported Q2 2026 results and an update on its Phase 2 silevertinib trial in frontline non-classical EGFRm NSCLC. At an April 11 cutoff, ORR was 60% and CNS ORR 86% (no de novo brain mets). Cash was $110.5M, expected to fund operations into 2H 2028; FDA feedback and a pivotal-path update are expected in Q4 2026.
Black Diamond Therapeutics, Inc. (BDTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001701541 0001701541 2026-06-26 2026-06-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
Black Diamond Therapeutics reported positive Phase 2 data for its lung cancer drug, silevertinib, showing a median progression-free survival of 15.2 months in treatment-naive non-small cell lung cancer patients with EGFR Non-Classical Mutations. The data also indicated a 60% objective response rate and an 86% central nervous system response rate. The company plans to discuss a pivotal development plan with the FDA, noting the tolerability profile was manageable with dose adjustments.
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) announced promising Phase 2 trial results for silevertinib in non-small cell lung cancer patients with EGFR non-classical mutations, showing positive efficacy and safety data. The trial's success led to a significant increase in share price, and the company plans to meet with the FDA to discuss pivotal development, with analysts raising price targets.
